TransMedics Group, Inc. (NASDAQ:TMDX) Given Average Recommendation of “Moderate Buy” by Brokerages

TransMedics Group, Inc. (NASDAQ:TMDX) has been given an average rating of “Moderate Buy” by the nine ratings firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $171.44.

TMDX has been the topic of a number of recent research reports. Needham & Company LLC initiated coverage on shares of TransMedics Group in a research note on Wednesday, August 21st. They issued a “buy” rating and a $208.00 price objective on the stock. Stephens raised their price objective on shares of TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Canaccord Genuity Group raised their price objective on shares of TransMedics Group from $117.00 to $169.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. TD Cowen raised their price objective on shares of TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a research note on Friday, June 7th. Finally, Cantor Fitzgerald began coverage on shares of TransMedics Group in a research note on Thursday, June 6th. They issued an “overweight” rating and a $161.00 price objective on the stock.

Insider Transactions at TransMedics Group

In related news, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $145.17, for a total value of $1,252,091.25. Following the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $8,948,714.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $145.17, for a total value of $1,252,091.25. Following the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $8,948,714.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director James R. Tobin sold 20,000 shares of the business’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $159.33, for a total transaction of $3,186,600.00. Following the completion of the sale, the director now directly owns 173,146 shares in the company, valued at $27,587,352.18. The disclosure for this sale can be found here. Insiders have sold a total of 52,622 shares of company stock valued at $8,327,633 over the last three months. 7.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On TransMedics Group

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Amalgamated Bank increased its stake in TransMedics Group by 6.7% in the 2nd quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock valued at $168,000 after buying an additional 70 shares during the last quarter. Pitcairn Co. increased its stake in TransMedics Group by 1.5% in the 1st quarter. Pitcairn Co. now owns 5,378 shares of the company’s stock valued at $398,000 after buying an additional 78 shares during the last quarter. Signaturefd LLC increased its stake in TransMedics Group by 26.6% in the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after buying an additional 93 shares during the last quarter. Arizona State Retirement System increased its stake in TransMedics Group by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock valued at $1,379,000 after buying an additional 186 shares during the last quarter. Finally, International Assets Investment Management LLC acquired a new stake in TransMedics Group in the 2nd quarter valued at $47,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Stock Performance

Shares of TransMedics Group stock opened at $151.42 on Friday. The company has a debt-to-equity ratio of 2.67, a current ratio of 9.37 and a quick ratio of 8.48. The firm has a market cap of $5.05 billion, a P/E ratio of -445.35 and a beta of 1.99. The firm has a 50 day simple moving average of $154.20 and a 200 day simple moving average of $126.66. TransMedics Group has a fifty-two week low of $36.42 and a fifty-two week high of $177.37.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.14. The business had revenue of $114.30 million during the quarter, compared to analyst estimates of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. TransMedics Group’s revenue for the quarter was up 117.7% compared to the same quarter last year. During the same quarter last year, the business posted ($0.03) earnings per share. Sell-side analysts predict that TransMedics Group will post 1.23 earnings per share for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.